Apoptosis and proliferation kinetics of T cells in patients having experienced antiretroviral treatment interruptions

Journal of Antimicrobial Chemotherapy

Volumn 52, Issue 2, 2003, Pages 269-275

  Roger, Pierre Marie ^a   Durant, Jacques ^a   Ticchioni, Michel ^a   Halfon, Philippe ^b   Breittmayer, Jean Philippe ^a   Brignone, Christelle ^a   Chaillou, Sylvie ^a   Dunais, Brigitte ^a   Dellamonica, Pierre ^a   Bernard, Alain ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b Hôpital de I'Archet 1 ^*

Author keywords

Apoptosis; HIV infection; Proliferation; Therapeutic interruption

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN;

ADULT; APOPTOSIS; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CELL KINETICS; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MALE; MONONUCLEAR CELL; MULTIDRUG RESISTANCE; PROSPECTIVE STUDY; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TIME; TREATMENT FAILURE; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; DRUG ADMINISTRATION SCHEDULE; HUMANS; LONGITUDINAL STUDIES; PROSPECTIVE STUDIES; T-LYMPHOCYTES;

EID: 0042028105     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg295     Document Type: Article

References (33)

1. Garcia, F., Plana, M., Vidal, C. et al. (1999). Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 13, F79-86.
2. Ruiz, L., Martinez-Picado, J., Romeu, J. et al. (2000). Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS 14, 397-403.
3. Lori, F., Lewis, M. G., Xu, J. et al. (2000). Control of SIV rebound through structured treatment interruptions during early infection. Science 24, 1591-3.
4. Garcia, F., Miro, J. M. & Gatell, J. M. (2000). Structured antiretroviral therapy interruption as a form of immune-based therapy in HIV-1 infection. AIDS Review 2, 3-8.
5. Katlama, C. (2000). Structured antiretroviral treatment interruption in heavily-experienced HIV-infected patients. AIDS Review 2, 9-14.
6. Pitcher, C. J., Quittner, C., Peterson, D. M. et al. (1999). HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nature Medicine 5, 518-25.
7. Montaner, L. J. (2001). Structured treatment interruptions to control HIV-1 and limit drug exposure. Trends in Immunology 22, 92-6.
8. Deeks, S. G., Wrin, T., Liegler, T. et al. (2001). Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. New England Journal of Medicine 344, 472-80.
9. Binley, J. M., Schiller, D. S., Ortiz, G. M. et al. (2000). The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy. Journal of Infectious Diseases 181, 1249-63.
10. Colven, R., Harrington, R. D., Spach, D. H. et al. (2000). Retroviral rebound syndrome after cessation of suppressive antiretroviral therapy in three patients with chronic HIV infection. Annals of Internal Medicine 133, 430-4.
11. Kilby, J. M., Goepfert, P. A., Miller, A. P. et al. (2000). Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report. Annals of Internal Medicine 133, 435-8.
12. Papasavvas, E., Ortiz, G. M., Gross, R. et al. (2000). Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. Journal of Infectious Diseases 182, 766-75.
13. Katsitkis, P. D., Wunderlich, E. S., Smith, C. A. et al. (1995). Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. Journal of Experimental Medicine 181, 2029-36.
14. Cottrez, F., Manca, F., Dalgleish, A. G. et al. (1997). Priming of human CD4+ antigen-specific T cells to undergo apoptosis by HIV-infected monocytes. Journal of Clinical Investigation 99, 257-66.
15. Roger, P. M., Breittmayer, J. P., Arlotto, C. et al. (1999). Highly active anti-retroviral therapy (HAART) is associated with a lower level of CD4+ T cell apoptosis in HIV-infected patients. Clinical and Experimental Immunology 118, 412-6.
16. Riss, T. L. & Movarec, R. A. (1992). Comparison of MTT, XTT, and a novel tetrazolium compound for MTS for in vitro proliferation and chemosensitivity assays. Molecular Biology of the Cell 3, Suppl. 1, 184-90.
17. Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunologic Methods 65, 55-63.
18. Durant, J., Clevenbergh, P., Halfon, P. et al. (1999). Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 353, 2195-9.
19. Hirsch, M. S., Brun-Vezinet, F., D'Aquila, R. T. et al. (2000). Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. Journal of the American Medical Association 283, 2417-26.
20. + T cell response. Journal of Immunology 168, 5455-64.
21. Tomiyama, H., Matsuda T. & Takiguchi, M. (2002). Differentiation of CD8+ T cells from a memory to memory/effector phenotype. Journal of Immunology 168, 5538-50.
22. Gea-Banacloche, J. C. & Clifford Lane, H. (1999) Immune reconstitution in HIV infection. AIDS 13, Suppl. A, S25-38.
23. McCune, J. M., Hanley, M. B., Cesar, D. et al. (2000). Factors influencing T-cell turnover in HIV-1-seropositive patients. Journal of Clinical Investigation 105, 1-8.
24. Hellerstein, M., Hanley, M. B., Cesar, D. et al. (2000). Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nature Medicine 5, 83-9.
25. D'Offizi, G., Montesano, C., Agrati, C. et al. (2002). Expansion of pre-terminally differentiated CD8 T cells in chronic HIV-positive patients presenting a rapid viral rebound during structured treatment interruption. AIDS 16, 2431-8.
26. Oxenius, A., Price, D. A., Günthard, H. F. et al. (2002). Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proceedings of the National Academy of Sciences, USA 99, 13747-52.
27. Foster, S., Beverley, P. & Aspinall, R. (1995). gp120-induced progammed cell death in recently activated T cells without subsequent ligation of the T cell receptor. European Journal of Immunology 25, 1778-82.
28. Skowron, G., Cole, B. F., Zheng, D. et al. (1997). gp120-directed antibody-dependent cellular cytotoxicity as a major determinant of the rate of decline in CD4 percentage in HIV-1 disease. AIDS 11, 1807-14.
29. Kang, Y., Marco Melo, E. F. & Scott, D. W. (1998). An ongoing immune response to HIV envelope gp120 in human CD4-transgenic mice contributes to T cell decline upon intravenous administration of gp120. European Journal of Immunology 28, 2253-64.
30. Keita-Perse, O., Roger, P. M., Pradier, C. et al. (1998). Do viral load and CD8 cell count at initiation of tritherapy influence the increase of CD4 T-cell count? AIDS 12, F175-9.
31. Roger, P. M., Breittmayer, J. P., Cottalorda, J. et al. (2001). Persistent viral load in patients on HAART is associated with a higher level of activation-induced apoptosis of CD4(+) T cells. Journal of Antimicrobial Chemotherapy 47, 109-12.
32. Garcia, F., Plana, M., Ortiz, G. M. et al. (2001). The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 15, F29-40.
33. Ruiz, L., Carcelin, G, Martinez-Picado, J. et al. (2001). HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS 15, F19-27.